8-K: Village Farms Achieves Record Q3 Performance, Boosts Cash

Village Farms International reported record financial results for the third quarter of 2025, driven by strong growth in its Canadian and Netherlands cannabis operations.

Summary

• Consolidated net sales increased 21% year-over-year to $66.7 million for the third quarter ended September 30, 2025.
• Consolidated net income from continuing operations was $10.8 million, or $0.09 per share, a significant improvement from a net loss of $0.8 million, or ($0.01) per share, in the prior year period.
• Consolidated Adjusted EBITDA reached a record $20.2 million, representing 30.3% of sales, compared to $5.3 million in the prior year period.
• Operating cash flow for the quarter was $24.4 million, bringing the year-to-date total to $46.7 million, and the company ended the quarter with approximately $88 million in cash.
• Canadian Cannabis segment delivered record net sales of $46.6 million (C$64.1 million), up 29% year-over-year, with international export sales increasing 758%.
• Canadian Cannabis gross margin increased to 56% from 26%, and net income surged 900% to $11.7 million (C$16.0 million).
• Netherlands Cannabis (Leli Holland) reported net sales of $3.6 million, net income of $0.8 million, and Adjusted EBITDA of $1.3 million, with its Phase I facility at full operating capacity.
• The U.S. Cannabis (Balanced Health Botanicals) segment saw net sales decrease to $3.3 million from $3.9 million, with a net loss of $0.4 million.
• Village Farms Produce sales were essentially flat at $12.8 million, but net income from continuing operations improved to $1.3 million from $0.3 million.
• The Board of Directors approved a US$10 million share repurchase authorization for up to 5,687,000 common shares on September 29, 2025.

Sentiment

Score: 9

Explanation: The company reported record financial performance across multiple key metrics, including consolidated net sales, net income, adjusted EBITDA, and operating cash flow. The Canadian cannabis segment showed exceptional growth and profitability, and the Netherlands cannabis operations are ramping up successfully with significant expansion plans. The initiation of a share repurchase program further signals management's confidence and commitment to shareholder returns. While the U.S. cannabis segment showed a slight decline, the overall performance is overwhelmingly positive and indicates strong operational execution and strategic positioning.

Positives

• Consolidated net sales increased 21% year-over-year to $66.7 million.
• Consolidated net income from continuing operations was $10.8 million, a substantial improvement from a net loss of $0.8 million in the prior year.
• Consolidated Adjusted EBITDA reached a record $20.2 million, representing 30.3% of sales, up from $5.3 million in the prior year.
• Consolidated operating cash flow was $24.4 million for the quarter, bringing year-to-date total to $46.7 million, significantly higher than $2.8 million year-to-date 2024.
• Cash position at quarter end was approximately $87.6 million, a strong increase from $24.6 million at December 31, 2024.
• Canadian Cannabis net sales increased 29% to $46.6 million (C$64.1 million).
• International medical export sales for Canadian Cannabis increased 758% year-over-year.
• Canadian Cannabis gross margin dramatically increased to 56% from 26%, driven by operating efficiency and higher-margin export sales.
• Canadian Cannabis net income increased 900% to $11.7 million (C$16.0 million).
• Canadian Cannabis Adjusted EBITDA increased 306% to $19.3 million (C$26.6 million).
• Canadian Cannabis cash flow from operations increased 331% to $19.4 million (C$26.8 million).
• Netherlands Cannabis (Leli Holland) generated $3.6 million in net sales, $0.8 million in net income, and $1.3 million in Adjusted EBITDA in its first operational quarter.
• Leli Holland's Phase I facility in Drachten has ramped to full operating capacity and its products are represented in 91% of participating coffeeshops.
• Village Farms Produce net income from continuing operations improved to $1.3 million compared to $0.3 million.
• Village Farms Produce Adjusted EBITDA from continuing operations improved to $2.5 million from $1.7 million.
• The company maintains a top five overall market share position in Canada and the number two position in dried flower.
• Initiation of a US$10 million share repurchase program, demonstrating confidence in the company's financial health and commitment to shareholder returns.

Negatives

• U.S. Cannabis (Balanced Health Botanicals) net sales decreased to $3.3 million from $3.9 million.
• U.S. Cannabis gross margin decreased to 60% from 63%.
• U.S. Cannabis net loss worsened to $0.4 million compared with a net loss of $0.2 million.
• U.S. Cannabis Adjusted EBITDA was a loss of ($0.3 million) compared with a loss of ($0.2 million).

Risks

• Limited operating history in the cannabis and cannabinoids industry, including Pure Sunfarms, Rose LifeScience, and Balanced Health Botanicals.
• Limited operational history of the Delta RNG Project in the energy segment and Leli Holland B.V.
• The legal status of the cannabis business and uncertainty regarding the legality and regulatory status of cannabis in the United States.
• Risks relating to the integration of Balanced Health and Rose into the consolidated business.
• Risks relating to obtaining additional financing on acceptable terms, including dependence upon credit facilities and dilutive transactions.
• Potential difficulties in achieving and/or maintaining profitability.
• Variability of product pricing.
• Risks inherent in the cannabis, hemp, CBD, cannabinoids, and agricultural businesses.
• Market position and competitive position.
• Ability to leverage current business relationships for future business involving hemp and cannabinoids.
• The ability of Pure Sunfarms and Rose to cultivate and distribute cannabis in Canada as well as exports.
• Risks related to the start-up of international production at Netherlands operations under Leli.
• Existing and new governmental regulations, including risks related to regulatory compliance and obtaining and maintaining licenses required under the Cannabis Act (Canada) and other acts.
• Legal and operational risks relating to expected conversion of greenhouses to cannabis production in Canada and in the United States.
• Risks related to rules and regulations at the U.S. Federal (Food and Drug Administration and United States Department of Agriculture), state, and municipal levels with respect to produce and hemp, cannabidiol-based products commercialization.
• Retail consolidation, technological advances, and other forms of competition.
• Transportation disruptions.
• Product liability and other potential litigation.
• Retention of key executives.
• Labor issues.
• Uninsured and underinsured losses.
• Vulnerability to rising energy costs.
• Inflationary effects on costs of cultivation and transportation.
• Recessionary effects on demand of products.
• Environmental, health, and safety risks.
• Foreign exchange exposure.
• Risks associated with cross-border trade and the potential for tariffs and other trade restrictions.
• Difficulties in managing growth.
• Restrictive covenants under credit facilities.
• Natural catastrophes.
• Elevated interest rates.
• Tax risks.

Future Outlook

The company remains highly motivated to exceed expectations and is confident in its ability to continue driving profitable sales growth and strong cash flow generation. Capacity expansion projects in Europe and Canada are expected to come online next year, supported by a strong balance sheet and a focus on continuous improvement. The company sees a very bright future as it executes its growth strategy and pursues various expansion opportunities globally, including potential entry into additional international medical markets in the first half of 2026 and a pending Texas medicinal marijuana license.

Management Comments

• "Another quarter of record financial performance that demonstrates our continued success profitably scaling what we believe is one of the most attractive platforms for value creation in the global cannabis industry."
• "Our team achieved several new performance records in Q3, with both year-over-year and sequential increases in each of net income from continuing operations, adjusted EBITDA and cash flow from operations."
• "Our significantly improved cash flow generation profile and balance sheet will enable us to continue expansion projects and possible strategic investments, and gave our Board of Directors confidence to initiate a share repurchase program at the end of the third quarter as part of a balanced approach to capital allocation to drive returns to shareholders."
• "With capacity expansion projects in Europe and Canada coming online next year, along with the strength of our balance sheet and our focus on continuous improvement, we see a very bright future for Village Farms as we continue executing our growth strategy and pursuing various expansion opportunities around the world."

Industry Context

Village Farms International's strong Q3 2025 results highlight a robust performance in the global cannabis industry, particularly in Canada and the nascent Netherlands market. The significant increase in international export sales for Canadian cannabis suggests a growing global demand for medical cannabis, where the company believes it is the largest exporter to Europe. The strategic shift towards higher-margin SKUs in Canada reflects an industry trend towards optimizing product portfolios for profitability. The expansion in the Netherlands positions the company to capitalize on the emerging recreational cannabis market in Europe. While the U.S. cannabis segment (CBD) faced headwinds, the company's diversified approach across produce, clean energy, and international cannabis markets provides resilience. The focus on capacity expansion in key growth areas indicates a proactive strategy to capture market share in a rapidly evolving global cannabis landscape.

Comparison to Industry Standards

• The Canadian Cannabis segment's gross margin of 56% significantly surpassed its targeted range of 30-40%, indicating superior operational efficiency and product mix compared to many industry peers who often struggle with profitability in the competitive Canadian market.
• The 758% year-over-year increase in international medical export sales demonstrates exceptional growth, positioning the company as a leading exporter to Europe, a market segment that is expanding rapidly and offers higher margins than domestic Canadian retail.
• The Netherlands operations, with products in 91% of participating coffeeshops, show strong market penetration for a new entrant in a highly regulated and experimental market, suggesting effective market entry and product acceptance compared to other licensed cultivators.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Highly positive impact due to record financial performance, significant increases in profitability and cash flow, and the initiation of a share repurchase program, indicating strong shareholder returns and confidence.
• Employees: Positive impact from continued growth and expansion projects in Canada and the Netherlands, potentially leading to increased job security, opportunities, and a stable work environment.
• Customers: Continued focus on product quality, new product introductions (e.g., packaging innovations, hash offerings, pre-rolls), and increased market penetration in cannabis segments suggest enhanced product offerings and accessibility.
• Creditors: Improved financial health, strong cash flow generation, and a robust balance sheet strengthen the company's ability to meet its financial obligations, reducing credit risk.
• Suppliers: Continued operational expansion and increased production capacity in cannabis segments may lead to increased demand for raw materials and services from suppliers.

Next Steps

• Canadian cannabis capacity expansion project to ramp through 2026, adding 40 metric tons of annualized production.
• Construction of the Netherlands Phase II facility in Groningen remains on track to be operational in Q1 2026, quintupling total annualized production capacity.
• Company anticipates entering additional international medical markets during the first half of calendar year 2026.
• Texas medicinal marijuana license awards are expected on December 1, 2025; if awarded, the company plans to structure ownership and comply with regulatory requirements.
• Management will host a conference call on November 10, 2025, to discuss the third quarter 2025 financial results.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with record consolidated net sales, net income, adjusted EBITDA, and operating cash flow. The Canadian cannabis segment is a standout, showing massive year-over-year growth in sales, gross margin, and profitability, while also expanding capacity. The Netherlands operations are successfully ramping up with significant future expansion planned. The company's strong balance sheet and cash position, coupled with the initiation of a share repurchase program, indicate robust financial health and a commitment to shareholder value. Despite minor headwinds in the U.S. cannabis segment, the overall trajectory and strategic initiatives position Village Farms for continued strong growth in the global cannabis market. This performance significantly exceeds prior periods and suggests a strong investment opportunity.

Keywords

Cannabis, Financial Results, Q3 2025, Village Farms International, VFF, Pure Sunfarms, Leli Holland, Adjusted EBITDA, Net Sales, Operating Cash Flow, Share Repurchase, Hemp, CBD, Controlled Environment Agriculture, Produce, Medical Cannabis, International Export